'Pluvicto is one of a new generation of so-called “radiopharmaceutical” therapies that can help cancer patients live longer, but are expensive to produce due to complex supply chains. The US list price of the drug is about $42,500 a dose, with a treatment cycle of up to six doses, but it is not offered by some European health systems.'

https://www.ft.com/content/1a1910e5-fd95-45f9-b8fd-adc4d7b3c8e7